Introduction {#s1}
============

Positive and negative selection of thymocytes generates a population of T lymphocytes with a broad spectrum of antigen-specific T cell receptors (TCR) ([@bib61]; [@bib35]). It was recognized early on that the small GTPase Ras plays a role ([@bib64]). Three Ras guanine exchange factor (RasGEF) families can activate Ras: SOS, RasGRP, and RasGRF ([@bib63]). Following TCR engagement, *Son of Sevenless* (SOS)-1 and -2 are recruited to the plasma membrane via a Grb2-phospho-LAT interaction. Simultaneously, the second messenger diacylglycerol (DAG), generated via PLCγ, directly recruits Ras guanine nucleotide releasing protein 1 (Rasgrp1) to the plasma membrane ([@bib18]). Biochemically, Rasgrp1 and SOS1 synergize to induce high-level Ras activation ([@bib53]) and Rasgrp1 serves a critical role in priming SOS1 via Rasgrp1-produced RasGTP ([@bib14]). Consequentially, thymocyte development is severely impaired in *Rasgrp1*-deficient mice ([@bib17]), and not compensated for by SOS RasGEFs. Additionally, there is only minimal compensation for loss of Rasgrp1 coming from Rasgrp3 or Rasgrp4 ([@bib76]; [@bib25]). *Rasgrp1*-deficient mice exhibit a strong defect in positive selection and impaired ERK phosphorylation in thymocytes ([@bib17]; [@bib46]). The importance of the canonical Rasgrp1-RasGTP-RAF-MEK-ERK pathway for developing thymocytes is further underscored by impaired positive selection in ERK-1 and -2 doubly deficient mice ([@bib20]).

Although Rasgrp1 plays a critical role in the activation of Ras, relatively little is known about its regulation in T lymphocytes or the in vivo importance of such regulation. In addition to membrane recruitment via its DAG-binding C1 domain ([@bib18]), Rasgrp1's GEF activity is enhanced by inducible phosphorylation of threonine 184 ([@bib52]; [@bib75]). Phospholipase C γ (PLCγ) not only generates DAG but also inositol 1,4,5-trisphosphate (IP3), which binds to IP3 receptors on the endoplasmic reticulum to activate the calcium pathway ([@bib19]). Interestingly, Rasgrp1 also contains a pair of EF hands, motifs that often bind calcium, which induces conformational changes ([@bib24]). Rasgrp1 has been reported to bind calcium in vitro ([@bib18]). In chicken DT40 B cells, the first EF~1~ domain enables the recruitment function of a C-terminal PT domain (plasma membrane targeting domain) that cooperates with the C1 domain to recruit Rasgrp1 to the membrane ([@bib65]). Notably, the PT domain contribution is substantial in BCR-stimulated B cell lines, very modest in T cell lines, and negligible in fibroblasts ([@bib7]). Genetic deletion of Rasgrp1's 200 C-terminal amino acids reduces the formation of mature thymocytes in *Rasgrp1*^*d/d*^ mice ([@bib21]). Our recent structural studies revealed that Rasgrp1's C terminus contains a coiled-coil dimerization domain ([@bib30]). Rasgrp1 dimerization plays an important role in controlling Rasgrp1's activity; the second EF hand of one Rasgrp1 molecule packs against the C1 domain of a second molecule in a manner that is incompatible with DAG-binding whereas calcium binding to the first EF hand is predicted to unlock this autoinhibitory dimer interface ([@bib30]). Lastly, it is unknown if Rasgrp1 may signal to pathways other than the canonical Rasgrp1-Ras-RAF-MEK-ERK cascade, although a link between Rasgrp1 and mTOR (mechanistic target of rapamycin) signaling has been proposed ([@bib26]).

Older *Rasgrp1*-deficient ([@bib12]) and *Rasgrp1*^*d/d*^ mice ([@bib21]) develop splenomegaly and autoantibodies. In these mouse models, the complete deletion or truncation of Rasgrp1 greatly decreases T cell development in the thymus ([@bib17]; [@bib21]), resulting in peripheral T cell lymphopenia followed by accumulation of CD44^hi^ CD62L^lo^ CD4^+^ T cells ([@bib45]; [@bib21]). Autoimmune phenotypes caused by these mutations have been attributed to compromised T cell selection in the thymus and compensatory expansion of peripheral T cells in response to lymphopenia and/or chronic infection. Hypomorphic missense alleles of the signaling molecules ZAP-70 and LAT also impair T cell development in the thymus and culminate in severe peripheral immune dysregulation. For example, an SKG allele of the kinase ZAP-70 has reduced binding-affinity for phospho-TCRζ and leads to autoimmune arthritis in mice ([@bib55]). Point mutations in ZAP70's catalytic domain that reduce kinase activity to intermediate levels diminish thymic deletion and Foxp3^+^ Treg differentiation but preserve peripheral T cell activation, resulting in autoantibody formation and hyper-IgE production ([@bib57]). Mutation of a single tyrosine in LAT (LAT^Y136F^) results in hyperproliferative lymphocytes of a T~H~2 type ([@bib3]; [@bib60]). In each of these cases, peripheral T cell dysregulation is tied to, and potentially explained by, profound deficits in thymic T cell formation.

Single nucleotide variants that cause amino acid substitutions (missense variants; SNVs) or modify the level of gene expression rather than knocking out protein expression are a major form of human genetic variation: most people inherit ∼12,000 missense gene variants ([@bib77]). Given the emerging examples of missense alleles having very different immunological consequences from null alleles, mouse models that analyze the consequences of missense variants in key immune genes are needed to understand the pathogenesis of complex human immune diseases. Common tag SNVs near *RASGRP1* are associated with susceptibility to autoimmune (Type 1) diabetes and to thyroid autoantibodies in Graves' disease ([@bib47]; [@bib42]), while 13 unstudied *RASGRP1* missense SNVs are currently listed in public databases. A fruitful approach for identifying missense gene variants that dysregulate immune function has been through *N*-ethyl-*N*-nitrosourea (ENU) mutagenesis ([@bib40]). Here we describe the analysis of a novel ENU-induced missense variant, *Rasgrp1*^*Anaef*^ that reveals an important in vivo regulatory function of Rasgrp1's EF hands. *Rasgrp1*^*Anaef*^ is distinct from previously described autoimmune mutations in *Rasgrp1*, *Zap70* or *Lat*, as *Rasgrp1*^*Anaef*^ has no detectable effect on thymocyte development in mice with normal TCR repertoires, but results in peripheral accumulation of a distinct population of Helios^+^ PD-1^+^ T-helper cells and production of anti-nuclear autoantibodies. In contrast to *Rasgrp1* deletion, the *Rasgrp1*^*Anaef*^ missense variant increases tonic mTOR signaling in naïve CD4^+^ T cells. Genetic reduction of mTOR function in *Rasgrp1*^*Anaef*^ mice normalizes CD44 expression on naïve CD4^+^ T cells and abolishes excessive accumulation of effector T cells and autoantibodies, demonstrating a central role for increased mTOR activity in driving immune dysregulation in *Rasgrp1*^*Anaef*^ mice.

Results {#s2}
=======

Identification of the *Rasgrp1*^*Anaef*^ mouse strain with a mutated EF hand in Rasgrp1 {#s2-1}
---------------------------------------------------------------------------------------

As part of a mouse genome-wide screen for immune phenotypes induced by ENU mutagenesis ([@bib40]), we identified a variant C57BL/6 (B6) pedigree displaying elevated frequencies of CD44^hi^ CD4^+^ cells ([Figure 1A](#fig1){ref-type="fig"}), elevated CD44 expression on naïve FOXP3^−^ CD44^lo^ CD4^+^ cells ([Figure 1B](#fig1){ref-type="fig"}) and antinuclear antibodies (ANAs) staining with a homogeneous nuclear pattern ([Figure 1C,D](#fig1){ref-type="fig"}). The elevated frequency of CD44^hi^ cells trait, which occurred at a frequency consistent with inheritance of a recessive gene variant ([Figure 1A](#fig1){ref-type="fig"}), was used to map the mutation in an F2 intercross to an interval between 114 and 121.2 Mb on chromosome 2 ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}).10.7554/eLife.01020.003Figure 1.An ENU mouse mutant with increased CD44hi CD4 cells and anti-nuclear autoantibodies.(**A** and **B**) Representative flow cytometry showing on peripheral blood CD4^+^ cells (**A**) CD44 expression with the gate used to define CD44^hi^ cells and (**B**) FOXP3 vs CD44 phenotype including normalized CD44 Mean Fluorescence Intensity (MFI) of the gated CD44^lo^ FOXP3^−^ subset from *Rasgrp1*^+/+^ (WT), heterozygous *Rasgrp1*^*Anaef*/+^ or homozygous *Rasgrp1*^*Anaef/Anaef*^ mice. Statistical analysis (right) used unpaired Student's t tests where each symbol represents an individual mouse; \*\*\*p\<0.001. (**C**) Antinuclear antibodies (ANA) in diluted blood plasma from a B6xB10. *Rasgrp1*^*Anaef*^ mouse and wildtype littermate, measured by indirect immunofluorescence on HEp-2 cells. Note homogeneous nuclear staining of interphase cells and positive chromatin bars in dividing cells (marked with arrow). Magnification 20 ×. (**D**) Quantitation of positive ANA results for wildtype, *Rasgrp1*^*Anaef*/+^ and *Rasgrp1*^*Anaef/Anaef*^ C57Bl/6xC57Bl/10 siblings tested at 15 weeks of age.**DOI:** [http://dx.doi.org/10.7554/eLife.01020.003](10.7554/eLife.01020.003)10.7554/eLife.01020.004Figure 1---figure supplement 1.Mapping and genotyping of the Rasgrp1 mutation in ENU mutant mice with anti-nuclear antibodies and CD44hi phenotype.(**A**) SNP analysis of a cohort of F2 mice generated by outcrossing a B6 animal identified as 'affected' with CBA, then incrossing F1 offspring to produce the (ENU.B6 × CBA/J) F2 animals listed. Phenotypes of affected mice tracked with a genomic region between 114--121.2 on chromosome 2. The Rasgrp1 gene lies in this interval. (**B**) Genotyping of *Rasgrp1*^*Anaef/Anaef*^, *Rasgrp1*^*Anaef/WT*^, and wildtype mice in the Roose lab was performed using MS-PCR as described ([@bib54]; [@bib9]). Products are wt: 202 bp and R519G: 223 bp. (**C**) Genotyping of *Rasgrp1*^*Anaef/Anaef*^, *Rasgrp1*^*Anaef/WT*^, and wildtype mice using Amplifluor PCR in the Goodnow Lab. The *Rasgrp1*^*Anaef*^ strain was established through ethylnitrosourea (ENU)-mediated mutagenesis of B6 mice at the Australian National University as previously described ([@bib50]).**DOI:** [http://dx.doi.org/10.7554/eLife.01020.004](10.7554/eLife.01020.004)

Sequencing of the exons of *Rasgrp1*, the only gene within this interval with a known immune function, identified an A to G missense mutation in codon 519 within exon 13 ([Figure 2A](#fig2){ref-type="fig"}). Whole-exome capture, sequencing and computational analysis of DNA from an affected mouse ([@bib4]) identified this mutation as the only novel single-nucleotide variant within the interval of interest on chromosome 2 (data not shown). The mutant codon, located in Rasgrp1's second EF hand (EF2), encodes a neutral amino acid glycine (G) instead of the normal arginine (R), a large polar molecule with a positive charge (Rasgrp1 R519G; [Figure 2A,B](#fig2){ref-type="fig"}). Rasgrp1's arginine residue at 519 is also found in Rasgrp-2, and -4, and in EF3 of calcium and integrin binding protein (CIB) ([Figure 2B](#fig2){ref-type="fig"}). EF hands typically come in pairs separated by a linker and calcium binding subsequently alters the angle between helices E and F in proteins such as calmodulin (CaM) ([Figure 2C](#fig2){ref-type="fig"}) ([@bib27]; [@bib24]). Unique to Rasgrp1, this linker is unusually short. Furthermore, biophysical studies revealed that Rasgrp1's EF2 does not bind calcium, that the E helix is non-existent in EF2, but instead has evolved as a critical loop forming an autoinhibitory interface with the C1 domain ([Figure 2D,E](#fig2){ref-type="fig"}) ([@bib30]).10.7554/eLife.01020.005Figure 2.Mapping of the ENU mutation to the autoinhibitory second EF hand domain in Rasgrp1.(**A**) Sequence trace of *Rasgrp1*^*Anaef*^ exon 13 aligned to wildtype Rasgrp1 sequence. (**B**) Sequence comparison of CaM (calmodulin), CIB (calcium and integrin binding protein) and Rasgrp1, -2, -3 and -4 EF hands with conserved residues highlighted. (Acidic, red; Basic, blue; Calcium-binding residues, highlighted in grey; ENU-mutated residue in green). (**C** and **D**) Model of a typical pair of EF hands with two calcium (Ca)-binding loops each flanked by N- and C-terminal α-helices based on CaM (**C**). Model including the atypical second EF hand in RasGRP1 (**D**). RasGRP1's second EF hand does not bind calcium and the E helix has evolved into an autoinhibitory domain ([@bib30]). (**E**) Linear schematic of Rasgrp1 protein domains, phosphorylation site threonine 184, and position of R519G mutation in the second EF hand that evolved into a domain for autoinhibition. (**F** and **G**) Western blot for Rasgrp1 protein in thymocytes from *Rasgrp1*^*Anaef/Anaef*^ (A/A), heterozygous *Rasgrp1*^*Anaef/WT*^ (A/+), heterozygous *Rasgrp1*^*Null/WT*^ (+/−), and wildtype (+/+) mice. Blot was reprobed for α tubulin as a loading control. Relative Rasgrp1 expression was calculated and is shown. Note the expression of Rasgrp1's typical doublet, thought to be due to alternative translation initiation ([@bib44]). Representative blots of at least three independent experiments.**DOI:** [http://dx.doi.org/10.7554/eLife.01020.005](10.7554/eLife.01020.005)

The ENU-generated allele was named '*Rasgrp1^Anaef^*' to reflect the combination of antinuclear antibody (ANA) production and the amino acid substitution in the EF hand. Genotyping of this mutation in multiple generations of B6 offspring ([Figure 1---figure supplement 1B,C](#fig1s1){ref-type="fig"}) demonstrated that inheritance of the *Rasgrp1^Anaef^* allele was well correlated with the immunological abnormalities described above and below. ANAs were present in 70% of homozygous *Rasgrp1^Anaef/Anaef^* mice and 35% of heterozygous *Rasgrp1^Anaef/+^* mice ([Figure 1D](#fig1){ref-type="fig"}), compared to 5% of wildtype B6 mice, indicating a gene dosage effect. The R519G substitution caused an approximate 40% decrease in Rasgrp1 protein levels in homozygous *Rasgrp1^Anaef/Anaef^* thymocytes ([Figure 2F](#fig2){ref-type="fig"}). Since heterozygous *Rasgrp1^+/−^* thymocytes express half the Rasgrp1 dosage ([Figure 2G](#fig2){ref-type="fig"}) but do not display an abnormal immune phenotype ([@bib17]), whereas heterozygous *Rasgrp1^Anaef/+^* mice do exhibit abnormal immune phenotypes ([Figure 1B,D](#fig1){ref-type="fig"}), we conclude that the immune dysregulation in mice bearing the *Rasgrp1^Anaef^* allele is caused by the specific R519G alteration and not simply by a reduction of Rasgrp1 protein levels. In the remainder of the manuscript we discuss the analysis of homozygous *Rasgrp1^Anaef/Anaef^* mice and refer to these as *Rasgrp1^Anaef^* mice.

*Rasgrp1*^*Anaef*^ preserves Rasgrp1 function for T cell selection in the thymus {#s2-2}
--------------------------------------------------------------------------------

Analysis of *Rasgrp1*^*Anaef*^ mice revealed a striking contrast to the published *Rasgrp1*-deficient and *Rasgrp1*^*d/d*^ mouse models, which have T cell developmental defects that result in low thymic T cell output ([@bib17]; [@bib45]; [@bib21]). The frequency and number of mature CD4^+^ and CD8^+^ single positive (SP) thymocyte subsets was normal in *Rasgrp1*^*Anaef*^ mice, whereas these subsets were markedly decreased in *Rasgrp1*^*−/−*^ (knockout) mice analyzed in parallel ([Figure 3A,B](#fig3){ref-type="fig"}). Unlike the knockout allele, the *Rasgrp1*^*Anaef*^ mutation did not decrease the frequency of CD69^hi^ TCRβ^hi^ cells amongst CD4^+^CD8^+^ double positive (DP) thymocytes ([Figure 3C](#fig3){ref-type="fig"}) or the number of Foxp3^+^ CD4SP cells in the thymus ([Figure 3B](#fig3){ref-type="fig"}). Even in bone marrow chimeras reconstituted with a mixture of CD45.2^+^ *Rasgrp1*^*Anaef*^ and CD45.1^+^ wildtype marrow, the *Rasgrp1*^*Anaef*^ thymocytes exhibited no competitive disadvantage as they matured from DP to SP cells ([Figure 3D](#fig3){ref-type="fig"}). Injection into mice of 5-bromo-2′-deoxyuridine (BrdU) to pulse-label a cohort of proliferating DP thymocytes followed by analysis on day 5 demonstrated that the kinetics of maturation into SP cells was unaffected by the *Rasgrp1*^*Anaef*^ mutation ([Figure 3E](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). There was also normal deletion of Vβ5^+^ and Vβ11^+^ SP thymocytes upon self-superantigen/I-E^k^ recognition in B10.Br mice ([Figure 3F](#fig3){ref-type="fig"}) and similar usage of TCRα Jα segments in wildtype and *Rasgrp1*^*Anaef*^ CD4SP thymocyte populations ([Figure 3G](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}). Thus, analysis of the thymus of *Rasgrp1*^*Anaef*^ mice with a diverse TCR repertoire revealed no abnormalities in positive selection, Foxp3^+^ T-regulatory (T-reg) cell differentiation or clonal deletion, in striking contrast to previously described *Rasgrp1* mutations.10.7554/eLife.01020.006Figure 3.*Rasgrp1*^*Anaef*^ differs from *Rasgrp1*^*null*^ by preserving T cell selection in the thymus.(**A**) CD4/CD8 phenotype of thymocytes in wildtype, *Rasgrp1*^*Anaef*^, and *Rasgrp1*^*-/-*^ mice. (**B**) Number of DP, CD4SP and CD8SP as well as Foxp3+ CD4SP thymocytes in wildtype (n = 36), *Rasgrp1*^*Anaef*^ (n = 35), and *Rasgrp1*^*−/−*^ (n = 3) mice. Student's *t* tests p value symbols: \*\*p\<0.005, \*p\<0.05. (**C**) Percentages of CD69^hi^ TCRβ^hi^ cells among DP cells. Representative of three mice per genotype. (**D**) Competitive repopulation of thymic subsets in irradiated CD45.1^+^ B6 recipient mice reconstituted with a mixture of CD45.1^+^ WT and CD45.2^+^ *Rasgrp1*^*Anaef*^ bone marrow cells. The percentage of CD45.2^+^ cells amongst the indicated thymocyte subsets was determined 8 weeks after reconstitution. Lines connect measurements from individual mice. Data are representative of three separate chimera cohorts. (**E**) Mixed bone marrow chimeras bearing CD45.1^+^ WT and either CD45.2^+^ WT or CD45.2+ *Rasgrp1*^*Anaef*^ hematopoietic cells were injected i.p. with 1 mg BrdU 5 days before analysis. The percentages of DP, CD4SP and CD8SP cells amongst BrdU-labeled CD45.2^+^ *Rasgrp1*^*Anaef*^ (black columns) or CD45.2^+^ WT (white columns) thymocytes were determined and the mean ± SEM (n = 5 mice per group) is shown. See [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"} for flow cytometry gates. (**F**) Mean ± SEM number of CD4SP thymocytes expressing TCR Vβ8, which is not superantigen reactive, or Vβ5 or Vβ11 that recognize endogenous retroviral superantigen presented by the I-E MHCII molecule, comparing B6 mice lacking I-E and B10.BR expressing the I-E (n = 3 mice per group compiled from two experiments). (**G**) Analysis of Jα usage in sorted CD4SP thymocytes of wildtype or *Rasgrp1*^*Anaef*^ mice following published methods. PCR was performed using serial 1:2 dilutions of template DNA with primer sets that reveal rearrangements proximal (Jα58, Jα49) or distal (Jα50, Jα22) to the two promoters. [Figure 2G](#fig2){ref-type="fig"} is representative of three independent experiments. See [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"} for details on promoter use, additional Jα segments, and published methods.**DOI:** [http://dx.doi.org/10.7554/eLife.01020.006](10.7554/eLife.01020.006)10.7554/eLife.01020.007Figure 3---figure supplement 1.Comparison of thymocyte maturation kinetics in WT and *Rasgrp1*^*Anaef*^.(**A**) Gating strategy to analyze thymocyte maturation kinetics in [Figure 2E](#fig2){ref-type="fig"}. Histograms and plots show CD45.2^+^ *Anaef* thymocytes in mixed chimeras bearing CD45.1^+^ WT plus CD45.2^+^ *Anaef* hematopoietic cells. The histogram second from the left shows gates defining BrdU^−^ and BrdU^+^ subsets of CD45.2^+^ *Anaef* thymocytes, each of which was analyzed for CD4 vs CD8 expression in the right two plots. The CD4/CD8 plots indicate that the BrdU^+^ subset has a higher frequency of SP cells, demonstrating the specificity of the BrdU^+^ gate. Gating defining DP, CD4SP and CD8SP subsets amongst BrdU^+^ cells (far right plot) were used to compile [Figure 2E](#fig2){ref-type="fig"}. (**B**) Analysis of Jα usage in sorted CD4^+^ SP thymocytes of wildtype or Anaef mice following published methods ([@bib1]). PCR was performed using serial 1:2 dilutions of template DNA with primer sets. Primer sequences for the PCR were identical to those formerly reported (identity of sequences between 129 mice and C57/Bl6 mice was verified in the databases). Two promoters regulate the rearrangements; TEA (T-Early-α), which regulated Jα61 to Jα50 and the Jα49 promoter that regulated Jα49 and more distal segments such as Jα22. As described, CD14 was used as control. A representative experiment with CD4^+^ SP from three independent experiments is shown here. We did not observe significant differences in Jα segments between DP thymocytes from wildtype and *Rasgrp1*^*Anaef*^ mice either (not shown).**DOI:** [http://dx.doi.org/10.7554/eLife.01020.007](10.7554/eLife.01020.007)

Anaef diminishes canonical Rasgrp1-Ras-ERK signaling in response to in vitro stimulation {#s2-3}
----------------------------------------------------------------------------------------

Despite the normal thymic development in *Rasgrp1*^*Anaef*^ animals, there was a striking biochemical effect of the *Rasgrp1*^*Anaef*^ mutation on activation of the canonical Rasgrp1-Ras-ERK signaling pathway in a range of in vitro stimulation assays. GFP-tagged wildtype- or *Anaef*- Rasgrp1 was transiently expressed in RasGRP1-deficient Jurkat cells (JPRM441) ([@bib52]), which were either left unstimulated or stimulated with a combination of PMA (a synthetic analog of diacylglycerol) and ionomycin (a calcium ionophore). Gating on cells with different GFP intensities ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}) revealed that Rasgrp1^Anaef^ was hypomorphic (partial loss of function) for activating the Ras-ERK pathway: in GFP^+^ cells expressing Rasgrp1^Anaef^ there was only low ERK phosphorylation (P-ERK) and this was only modestly increased when PMA and ionomycin were added ([Figure 4A](#fig4){ref-type="fig"}). By contrast, GFP^+^ cells expressing high levels of wildtype Rasgrp1 vector induced 5-times higher P-ERK spontaneously and this was doubled by PMA and ionomycin stimulation. Next, we stably reconstituted the JPRM441 cell line, which expresses ∼10% of residual wildtype RasGRP1 protein ([@bib52]) with *Rasgrp1*^*Anaef*^ or *Rasgrp1*^*wildtype*^ vectors and selected clones with Rasgrp1 expression levels similar to the parental Jurkat cell line ([Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}). Since JPRM441 cells do not express surface TCR ([@bib52]), clonal cell lines were stimulated with PMA followed by RasGTP pull-down assays, which demonstrated that *Rasgrp1*^*Anaef*^ decreased PMA-induced GTP-loading of Ras to levels below that of the nontransfected JPRM441 cells ([Figure 4B](#fig4){ref-type="fig"}). In the same transfected cell lines, PMA-induced P-ERK responses were decreased in *Rasgrp1*^*Anaef*^ expressing cells, most notable with the lower dose of PMA (PMA MED; 5 ng/ml) and contrasted the effective induction of P-ERK signals in Jurkat and JPRM441-WT-Rasgrp1 cells ([Figure 4C,D](#fig4){ref-type="fig"}). Similarly, *Rasgrp1*^*Anaef*^ expressing cells demonstrated less potent synergy in P-ERK levels when ionomycin was combined with a very low PMA stimulus (2 ng/ml) ([Figure 4E](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}). In fact, P-ERK responses in JPRM441-Rasgrp1^Anaef^ cells were more impaired than in the parental JPRM441 cells, indicating a dominant negative effect, which was also observed at the level of Ras activation ([Figure 4B](#fig4){ref-type="fig"}). We previously reported a dominant negative effect for ΔDAG-Rasgrp1, a form of Rasgrp1 lacking the DAG-binding C1 domain (ΔDAG) and we postulated that there may be competition with the residual ∼10% of wildtype RasGRP1 ([@bib52]). As Rasgrp1 is regulated by DAG-driven membrane recruitment ([@bib18]; [@bib52]) we examined this process for Rasgrp1^Anaef^. EGFP-tagged wildtype or *Anaef* Rasgrp1-transfected JPRM441 cells were FACS sorted on low GFP expression to avoid overexpression artifacts and cells were allowed to adhere to coated slides. PMA stimulation resulted in membrane recruitment and cytoplasmic clearing of wildtype Rasgrp1; whereas these events were decreased for Rasgrp1^Anaef^ ([Figure 4F](#fig4){ref-type="fig"}).10.7554/eLife.01020.008Figure 4.Rasgrp1^Anaef^ diminishes in vitro signaling to Ras and ERK.(**A**) RasGRP-1 deficient Jurkat cells (JPRM441) were transiently transfected with EGFP-tagged wildtype- or Anaef-RasGRP1 and RasGRP1-dose/P-ERK responses were determined by FACS. (**B**) Jurkat, JPRM441, and JPRM441 cells stably reconstituted with Anaef- or WT Rasgrp1 were left unstimulated or stimulated with 25 ng/ml PMA and RasGTP levels were determined through a RasGTP pull down assay. (**C**--**E**) The indicated cell lines were stimulated for 0, 1, 5, 10, or 30 min (see key) with a high (25 ng/ml, **C**), medium (5 ng/ml, **D**), or low dose (2 ng/ml, **E**) of PMA, or with 2 ng/ml PMA with ionomycin (1 μM) and stained for intracellular phosphorylated-ERK-1 and -2 (P-ERK), and analyzed by flow cytometry. Results for JPRM441-Rasgrp1Anaef clones \#68 are shown, similar results were obtained with clone \#69. (**F**) EGFP-tagged constructs were transiently transfected into JPRM441 and RasGRP1 localization was determined for unstimulated and PMA-stimulated cells as described in the text. 50 images for the 2-min PMA stimulation were scored in a blinded manner and plotted with RasGRP1-Anaef in the black columns.**DOI:** [http://dx.doi.org/10.7554/eLife.01020.008](10.7554/eLife.01020.008)10.7554/eLife.01020.009Figure 4---figure supplement 1.Biochemical aspects of the *Rasgrp1*^*Anaef*^ allele.(**A**) Gating strategy for transiently expressed RasGRP1-EGFP in JPRM441 cells and analysis of ERK phosphorylation of cells expressing increasing doses of wildtype of Anaef RasGRP1 as depicted in the blue (second), green (fourth), and orange (sixth) color-coded cell populations, compared to ERK phosphorylation without transfected RasGRP1 in the filled brown histogram. (**B**) JPRM441 were stably reconstituted with a construct expressing Rasgrp1^Anaef^ (clones \#67, 68, 69). Protein lysates from an equivalent number of cells were probed for expression of Rasgrp1 and α tubulin (loading control). Percent expression of Rasgrp1 in each cell line (relative to the parental wildtype Jurkat) is shown. Rasgrp1Anaef protein levels in clones \#68 and \#69 were similar to those found in the parental Jurkat cell line and to expression of wildtype Rasgrp1 in a reconstituted JPRM441 clone 208 that we previously characterized ([@bib52]) and were utilized in subsequent assays. (**C**) Ionomycin-induced P-ERK responses. The depicted stable cell lines were stimulated with ionomycin (1 μM) for the indicated times and stained for intracellular p-ERK. Representative histograms are shown.**DOI:** [http://dx.doi.org/10.7554/eLife.01020.009](10.7554/eLife.01020.009)

To test TCR-induced Ras-ERK signaling in thymocytes, we first stimulated thymocytes from wildtype or *Rasgrp1*^*Anaef*^ mice with anti-CD3 crosslinking antibodies and probed lysates for tyrosine-phosphorylated proteins to examine the global biochemical effects of the *Rasgrp1*^*Anaef*^ mutation. Both thymocyte populations demonstrated similar induction of total phospho-tyrosine patterns and similar activating phosphorylation of Lck and Zap-70 that lie upstream of Rasgrp1 ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). Rasgrp1's GEF activity is also enhanced by phosphorylation on T184 ([@bib52]; [@bib75]). Using a new monoclonal antibody specific for P-T~184~-Rasgrp1 ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}) we observed drastically impaired phosphorylation of T~184~-Rasgrp1, and reduced ERK phosphorylation in *Rasgrp1*^*Anaef*^ thymocytes ([Figure 5A](#fig5){ref-type="fig"}). By contrast, *Rasgrp1*^*+/−*^ thymocytes heterozygous for the null allele displayed readily detectable Rasgrp1- and ERK- phosphorylation ([Figure 5B](#fig5){ref-type="fig"}), demonstrating that the signaling defects in the *Rasgrp1*^*Anaef*^ thymocytes are much greater than when the amount of Rasgrp1 is simply halved. Thymocyte subset-specific P-ERK analyses revealed reduced anti-CD3- and PMA-induced responses in DP, CD4SP, and CD8SP *Rasgrp1*^*Anaef*^ thymocytes ([Figure 5C](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}), echoing the cell line conclusion that the *Anaef* mutation results in a partial loss of function with respect to induced Ras-ERK signaling. When pressure was placed on TCR-Ras-ERK signaling for positive selection in vivo, by introducing any one of three different rearranged TCR transgenes that are prematurely expressed at higher than normal levels on DP thymocytes, a small decrease in positive selection was revealed in *Rasgrp1*^*Anaef*^ TCR-transgenic thymocytes compared to their wildtype controls ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}). Collectively, these results lead to the surprising conclusion that the low affinity pMHC stimulation that drives physiological positive selection in vivo is remarkably robust to decreased Rasgrp1 activation of Ras-ERK.10.7554/eLife.01020.010Figure 5.*Rasgrp1*^*Anaef*^ signaling characteristics of in vitro stimulated thymocytes.(**A** and **B**) Phosphorylation of PLCγ1, Rasgrp1, and ERK in total thymocytes from *Rasgrp1*^*Anaef*^ and age-matched WT mice or *Rasgrp1*^*+/−*^ and age-matched WT mice stimulated with anti-CD3 antibodies. (**C**) P-ERK induction by in vitro stimulation followed by intracellular flow cytometric staining and electronic gating on thymocyte subsets. Thymocytes from *Rasgrp1*^*Anaef*^ and age-matched WT mice were stimulated with anti-CD3 antibody (5 μg/ml) and crosslinked using secondary antibody (Goat anti-hamster, 20 μg/ml) for the indicated time points, fixed, and stained for intracellular p-ERK. Histograms show P-ERK staining on electronically gated DP, CD4SP or CD8SP thymocytes. These conditions yielded low-levels of ERK phosphorylation that is typically observed for wildtype DP thymocytes. Numbers indicate the percentages of cells above the arbitrarily set reference point in the histograms so that it can be appreciated how many cells within each population cross this P-ERK threshold. Data is representative of three independent experiments. For PMA-induced responses see [Figure 5---figure supplement 1D](#fig5s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.01020.010](10.7554/eLife.01020.010)10.7554/eLife.01020.011Figure 5---figure supplement 1.Signaling characteristics of *Rasgrp1*^*Anaef*^ thymocytes.(**A**) Thymocytes from *Rasgrp1*^*Anaef*^ and age-matched WT mice were stimulated with anti-CD3 antibody (clone 2C11, 10 μg/ml) and whole cell lysates were analyzed for induction of tyrosine phosphorylated proteins (4G10) and for specific phospho-Lck and phospho-Zap70 residues. ? tubulin is a loading control. Surface TCR expression levels on *Rasgrp1*^*Anaef*^ thymocytes were indistinguishable from wildtype (data not shown). (**B**) Characterization of JR-pT184RG1-2G9 monoclonal antibody. Whole cell lysates (WCL) or RasGRP1 immunoprecipitations with m133 monoclonal antibody of the indicated cell samples were subjected to western blot analysis with JR-pT184RG1-2G9 antibody. Note the induction of phosphorylated RasGRP1 in PMA-stimulated Jurkat cells and the reduction of this phosphor-RasGRP1 species in JPRM441 cells. Backblotting for total RasGRP1 levels was performed using a JR-E80-2 monoclonal antibody that recognizes human RasGRP1. (**C**) P-ERK induction by intracellular flow cytometric staining and electronic gating on thymocyte subsets following in vitro stimulation. Thymocytes from *Rasgrp1*^*Anaef*^ and age-matched WT mice were stimulated with PMA (30 ng/ml) for the indicated time points, fixed, and stained for intracellular p-ERK. Histograms show P-ERK staining on electronically gated CD4^+^CD8^+^ (double positive) and CD4^+^ or CD8^+^ single positive thymocytes.**DOI:** [http://dx.doi.org/10.7554/eLife.01020.011](10.7554/eLife.01020.011)10.7554/eLife.01020.012Figure 5---figure supplement 2.Thymic selection in *Rasgrp1*^*Anaef*^ mice carrying transgenic TCRs.*Rasgrp1*^*Anaef*^ mice demonstrate a two to sixfold decrease in positive selection in the context of three different transgenic TCRs that are uniformly and strongly expressed early on during thymocyte development. (**A**) Representative CD4/CD8 phenotype of the thymus after reconstitution of irradiated B10.BR mice with 3A9 TCR transgenic bone marrow that was either WT or Anaef. Means and SEM number of CD4SP cells are shown on the right. Statistics used unpaired Student\'s *t* test (n = 5 per group). \*p\<0.05. (**B**) Representative flow cytometry plots and quantitiation of thymocytes in HY TCR transgenic females that facilitate positive selection of CD8 cells on MHCI. Total cell counts with mean and standard error are shown on the right (n = 4 mice). \*p\<0.05. (**C**) Representative flow cytometry plots and quantitation of thymocytes in OTII TCR transgenic mice in which CD4 SP are selected on MHCII. Representative plots and total cell counts are shown (n = 6 mice). Student\'s *t* tests p value symbols: \*\*p\<0.005, \*p\<0.05.**DOI:** [http://dx.doi.org/10.7554/eLife.01020.012](10.7554/eLife.01020.012)

Intrinsically dysregulated formation of Helios^+^ PD-1^+^ CD4^+^ T cells in *Rasgrp1*^*Anaef*^ mice {#s2-4}
---------------------------------------------------------------------------------------------------

Given the evidence above for normal thymic formation of T cells in *Rasgrp1*^*Anaef*^ animals with normal TCR genes, we sought to define the peripheral CD4^+^ cell dysregulation that results in an expanded population of CD44^hi^ CD4^+^ T cells. Total splenocyte numbers and CD4 subsets were within the normal range in young *Rasgrp1*^*Anaef*^ animals, but between 50 and 150 days of age the frequencies of activated or memory CD44^hi^ Foxp3^−^ CD4^+^ cells increased, as did Foxp3^+^ CD4 cells, while the frequency of CD44^low^ Foxp3^−^ naïve CD4^+^ cells decreased ([Figure 6A--C](#fig6){ref-type="fig"}).10.7554/eLife.01020.013Figure 6.*Rasgrp1*^*Anaef*^ results in dysregulation of peripheral CD4 T cells.(**A**) Representative plots of wildtype or *Rasgrp1*^*Anaef*^ CD4^+^ splenocytes subsetted into naïve (CD44^lo^ FOXP3^−^), activated/memory (CD44^hi^ FOXP3^−^), and T-reg (FOXP3^+^) populations. (**B** and **C**) Splenic cellularity and frequencies of the CD4^+^ subsets gated in (**A**) as a function of age in wildtype vs *Rasgrp1*^*Anaef*^ mice; each dot represents one mouse (WT in white; *Rasgrp1*^*Anaef*^ in black). Inset column graphs show the group mean ± SEM. Statistics obtained by unpaired Student's *t* test. \*\*\*p\<0.001, \*\*\*\*p\<0.0001. (**D**) Representative intracellular labeling of IFNγ, IL-4, IL-2 or IL-17 on electronically gated Foxp3^−^ CD4^+^ wildtype or *Rasgrp1*^*Anaef*^ splenocytes that had been stimulated with PMA and ionomycin for 4 hr. Column graphs show mean ± SEM frequencies amongst all splenocytes. Statistical analysis of % IFNγ^+^ cells used an unpaired Student's *t* test (n = 7 WT, 6 *Anaef*) \*\*p\<0.01. (**E**) Phenotype of CD4^+^ splenocytes showing a CXCR5^+^ PD-1^hi^ gate for the T~FH~ population (left) and a gate for the HELIOS^+^ PD-1^+^ population amongst Foxp3^−^ CD4^+^ splenocytes (right). Column graph shows mean ± SEM frequencies of these populations amongst CD4^+^ splenocytes in wildtype or *Rasgrp1*^*Anaef*^ mice. Statistical analyses used unpaired Student's *t* tests (n = 19 WT, 18 *Anaef*). \*\*\*p\<0.001, \*\*\*\*p\<0.0001. (**F**) Helios vs CD44 phenotype of Foxp3^−^ CD4^+^ splenocytes (left plots) showing the gate for the CD44^hi^ population, which was analyzed for expression of Helios and PD-1 (right plots). Column graph shows the mean ± SEM number of splenocytes within the CD44^hi^ Foxp3^−^ CD4^+^ subpopulations gated in the right plots (n = 19 WT, 20 *Anaef* mice aged \>70 days and compiled from 11 separate experiments). Unpaired Student's *t* test \*\*p\<0.01. (**G**) Phenotype of B220^+^ splenocytes showing the CD95(Fas)^hi^ GL-7^hi^ gate used to define germinal center B cells (left), the mean ± SEM frequency of which is shown in the column graph (right) (n = 7 WT, 5 *Anaef*).**DOI:** [http://dx.doi.org/10.7554/eLife.01020.013](10.7554/eLife.01020.013)

Further resolution of CD4^+^ subsets based on intracellular cytokine staining revealed that interferon-γ producing cells were increased in frequency by a similar magnitude as CD44^hi^ cells as a whole ([Figure 6D](#fig6){ref-type="fig"} and data not shown). Thus, there was no evidence that the *Rasgrp1^Anaef^* mutation skewed T-helper cells towards a Th1 phenotype, but simply increased the number of activated or memory/effector CD4^+^ cells. Staining for PD-1 and CXCR5, whose high expression on CD4^+^ cells identifies T follicular helper (T~FH~) cells ([@bib49]) revealed a dramatic expansion of these cells in *Rasgrp1*^*Anaef*^ mice ([Figure 6E](#fig6){ref-type="fig"}). However most of the increase in CD44^hi^ Foxp3^−^ CD4^+^ cells in *Rasgrp1*^*Anaef*^ mice was due to a 600% increase in cells that expressed intermediate levels of PD-1 and CXCR5, and hence are unlikely to be T~FH~ cells, but were distinguished by high expression of the Helios transcription factor ([Figure 6E](#fig6){ref-type="fig"}). Helios is highly expressed in Foxp3^+^ T-reg cells ([@bib66]), but in wildtype and *Rasgrp1*^*Anaef*^ mice Helios is also upregulated in a subset of Foxp3^−^ CD4^+^ cells, nearly all of which are CD44^hi^ ([Figure 6F](#fig6){ref-type="fig"}). *Rasgrp1*^*Anaef*^ greatly increased this Helios^+^ CD44^hi^ Foxp3^−^ CD4^+^ population, which was also distinguished by high PD-1 expression in *Rasgrp1*^*Anaef*^ ([Figure 6F](#fig6){ref-type="fig"}). *Rasgrp1*^*Anaef*^ mice had normal frequencies of CD95 (Fas)^+^ GL-7^+^ germinal center B cells in the spleen ([Figure 6G](#fig6){ref-type="fig"}), consistent with the conclusion that the accumulating Helios^+^ PD-1^+^ CXCR5^int^ Foxp3^−^ CD44^hi^ CD4^+^ cells were a distinct type of activated CD4^+^ cell but not fully differentiated T~FH~ cells.

To test if the dysregulated accumulation of Helios^+^ PD-1^+^ CXCR5^int^ CD44^hi^ CD4^+^ T cells in *Anaef* mice required B cells, *Rasgrp1*^*Anaef*^ animals were intercrossed with mice bearing a null mutation in the BCR subunit, CD79a ([@bib70]). In *Rasgrp1*^*Anaef*^ *Cd79a*^*null*^ animals lacking B cells, accumulation of PD-1^+^ Helios^+^ CD4^+^ T cells was profoundly suppressed ([Figure 7A,B](#fig7){ref-type="fig"}). Indeed, the *Rasgrp1*^*Anaef*^--driven distortion in relative frequencies of naïve, effector/memory and regulatory subsets of CD4 splenocytes was rectified by the absence of B cells in *Rasgrp1*^*Anaef*^ *Cd79a*^*null*^ mice ([Figure 7C,D](#fig7){ref-type="fig"}). By contrast, the elevated CD44 expression on naïve CD4^+^ cells was still present ([Figure 7E](#fig7){ref-type="fig"}) indicating this is a constitutive effect of the *Rasgrp1*^*Anaef*^ mutation.10.7554/eLife.01020.014Figure 7.Role of B and T cells in *Rasgrp1*^*Anaef*^-induced Helios^+^ PD-1^+^ CD4^+^ T cell and autoantibody formation.(**A**--**E**) B6.*Cd79a*^*−/−*^ mice lacking B cells were intercrossed with B6.*Rasgrp1*^*Anaef*^ mice to produce mice with the genotypes shown above the plots. Plots (left) display phenotype of (**A** and **B**) Foxp3^−^ CD4^+^ splenocytes and the gate used to define the PD-1^+^ HELIOS^+^ subpopulation and absolute numbers of these cells are shown on the column graphs (mean ± SEM). Statistical comparisons used unpaired Student's *t* tests (n = 4 WT, 5 *Anaef*, 2 *CD79a-null*, and 4 *Anaef.CD79a-null*) \*p\<0.05. (**C**) CD4^+^ splenocytes and the gates used to define FOXP3^+^ regulatory, CD44^hi^ FOXP3^−^ effector/memory, and CD44^lo^ FOXP3^−^ naïve subsets. Absolute numbers of effector/memory splenocytes (**D**) and Relative CD44 expression on naive splenocytes (**E**) are shown in the column graphs (mean ± SEM). Statistical comparisons used unpaired Student's *t* tests (n = 4 WT, 5 *Anaef*, 2 *CD79a-null*, and 4 *Anaef.CD79a-null*) \*p\<0.05, \*\*\*p\<0.001. (**F**) Experimental design to delineate role of *Rasgrp1*^*Anaef*^ in T and B cells. Irradiated mice received either 100% *Rasgrp1*^WT^ marrow, 100% *Rasgrp1*^*Anaef*^ marrow, or a 1:4 mixture of CD45.1^+^ wild-type marrow mixed with CD45.2^+^ marrow from either *Cd79a*^*null/null*^*Rasgrp1*^WT^ or *Cd79a*^*null/null*^ *Rasgrp1*^Anaef^ siblings. (**G**) Incidence of homogeneous nuclear ANA in blood plasma in chimeric mice collected 18 weeks after irradiation, measured by immunofluorescence on HEp-2 cells and scored in a blinded manner. (**H**) Representative plots (left), and (I) quantification of frequency (middle) and number (right) of PD-1^+^ Helios^+^ cells among Foxp3^−^ CD4^+^ splenocytes from mixed chimeras in groups A and B as described in (**F**) 45 weeks after irradiation. Lines in (**I**) connect measurements from individual mice. Statistical analysis used paired Student's *t* tests within groups and unpaired *t* tests between groups. \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001.**DOI:** [http://dx.doi.org/10.7554/eLife.01020.014](10.7554/eLife.01020.014)

The requirement for B cells could indicate they are needed as specialized antigen presenting cells, as is the case for T~FH~ cells ([@bib49]), or that the *Anaef* mutation also acts in B cells since B cells also express Rasgrp1 ([@bib63]). To resolve these alternatives, we used bone marrow from *Rasgrp1*^*Anaef*^ *Cd79a*^*null*^ animals mixed with wildtype *Rasgrp1*^*+/+*^ marrow to generate chimeric mice where the *Rasgrp1*^*Anaef*^ mutation was excluded from B cells but present in most of the T cells (experimental group B in [Figure 7F--I](#fig7){ref-type="fig"}), and compared these with control chimeras where all hematopoietic cells were *Rasgrp1*^*Anaef*^ or *Rasgrp1*^*WT*^ (groups A, C and D in [Figure 7](#fig7){ref-type="fig"}). Despite having the *Anaef* mutation in the T but not B cells of group B mice, a high proportion developed antinuclear autoantibodies comparable to the control group D where both B and T cells carried the *Anaef* mutation ([Figure 7G](#fig7){ref-type="fig"}). Moreover, a high frequency and number of CD45.2^+^ *Rasgrp1*^*Anaef*^ CD4^+^ T cells acquired a Helios^+^ PD-1^+^ phenotype in Group B animals, unlike the co-resident CD45.1^+^ wildtype T cells ([Figure 7I](#fig7){ref-type="fig"}). The accumulation of these activated CD4 T cells thus reflects a cell-autonomous effect of the *Anaef* mutation within the CD4 T cells and does not depend upon the *Anaef* allele being present in B cells.

CD44 expression is a sensitive reporter of mTOR activity in naïve T cells {#s2-5}
-------------------------------------------------------------------------

Increased basal expression of the cell adhesion receptor, CD44, was a unique trait exhibited by naïve, CD62L-positive *Rasgrp1*^*Anaef*^ T cells ([Figure 1B](#fig1){ref-type="fig"}). CD44 expression normally increases during differentiation of DP thymocytes into SP T cells, attains higher levels on naïve CD4 T cells than on naïve CD8 cells, and increases further on activated/memory T cells, but little was known about what determines the level of CD44 expressed. In cancer cells CD44 has been described as an mTOR target ([@bib29]). In our ongoing peripheral blood screen of ENU mutagenized mouse pedigrees, we identified a strain, *chino*, with decreased CD44 expression on peripheral CD4^+^ CD62L^hi^ cells but relatively normal T cell numbers and subsets ([Figure 8A](#fig8){ref-type="fig"}). This unusual phenotype mapped to a single nucleotide change (T to G) in exon 5 of the mechanistic target of rapamycin (*Mtor*) gene, introducing serine in place of isoleucine at position 205 in the fifth predicted HEAT domain of the protein ([@bib34]) ([Figure 8B](#fig8){ref-type="fig"}). This mTOR isoleucine residue is entirely conserved from mammals to yeast ([Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}). The mTOR HEAT-repeat domain forms a large superhelical structure that binds RAPTOR to recruit substrates such as S6 kinase for phosphorylation by the mTOR kinase domain ([@bib32]; [@bib2]).

As the absence of *Mtor* is embryonic lethal in mice ([@bib22]; [@bib39]), the fact that *Mtor*^*chino/chino*^ (hereafter referred to as *Mtor*^*chino*^) mice are viable but slightly smaller than wildtype ([Figure 8C](#fig8){ref-type="fig"}) indicates that the *Mtor*^*chino*^ allele retains substantial function. Consistent with a subtle decrease in mTOR activity, TCR-induced phosphorylation of ribosomal protein S6 (P-S6) was modestly decreased but not abolished in *Mtor*^*chino*^ CD4^+^ splenocytes ([Figure 8D](#fig8){ref-type="fig"}). The numbers of DP, CD4SP and CD8SP thymocytes were normal in *Mtor*^*chino*^ mice ([Figure 8E](#fig8){ref-type="fig"}). Whereas expression of CD69, CD5 and TCRβ on DP and SP thymocytes was normal, CD44 expression was decreased on *Mtor*^*chino*^ CD4SP and CD8SP thymocytes ([Figure 8F](#fig8){ref-type="fig"}). CD44 expression on peripheral blood CD4^+^ T cells decreased in an *Mtor*^*chino*^ allele dose-dependent manner ([Figure 8G](#fig8){ref-type="fig"}), demonstrating that CD44 expression is a highly sensitive reporter of small changes in basal mTOR activity in CD4^+^ T cells. This conclusion is reinforced by supplementary data from two studies: mice with a *neo*-insertion in an *Mtor* intron that decreases *Mtor* mRNA approximately 70% show a similar selective lowering of CD44 on CD4^+^ T cells ([@bib74]) and CD44 levels are also reduced on naïve, CD62L-positive T cells that are deficient for the mTOR activator Rheb or deficient for the mTOR-interacting protein Rictor ([@bib16]). Furthermore, we found that pharmacological inhibition of mTOR with rapamycin in mice treated with low doses that avoid toxicity ([@bib11]; [@bib5]), resulted in a dose-dependent decrease in CD44 expression on wildtype and *Rasgrp1*^*Anaef*^ thymocytes ([Figure 8H](#fig8){ref-type="fig"}).10.7554/eLife.01020.015Figure 8.CD44 is a sensitive reporter of mTOR activity in immature and naïve CD4^+^ T cells.(**A**) CD44^lo^ T cell phenotype upon which *Mtor*^*chino*^ mice were identified. Phenotype of Foxp3^−^ CD4^+^ splenocytes from *Mtor*^*+/+*^ (WT) and *Mtor*^*chino/chino*^ (*chino*) mice, showing the CD62L^hi^ subset on which CD44 expression was quantified and normalized to the mean of WT animals (mean ± SEM from three experiments shown below). (**B**) Schematic of mTOR protein showing functional domains and the *chino* I205S mutation in the fifth HEAT repeat. (**C**) Reduced body size in *chino*. Body mass vs age of WT (black dots; 10 female \[top\], 11 male \[bottom\]) or *chino* (unfilled dots; three female, two male) mice. Curves were fitted to the WT datasets using second order polynomial equations; dotted lines show 95% prediction bands (the area expected to enclose 95% of future WT data points; GraphPad Prism version 5.0d for MAC OS X). Straight lines connect multiple measurements of individual *chino* mice. (**D**) Splenocytes from WT or *chino* mice were left unstimulated or were stimulated with PMA (100 ng/ml) for 10 min, fixed, and stained for intracellular phosphorylated-S6 (P-S6). Histogram overlay shows P-S6 staining on CD4^+^ cells representative of two separate experiments. (**E**) Number of DP, CD4SP and CD8SP cells per thymus of WT (n = 7) or *chino* (n = 7) mice compiled from four experiments. (**F**) Selective reduction in CD44 expression on *chino* thymocytes. Histograms show CD44, CD5, CD69 or TCRb expression on gated DP, CD4SP or CD8SP thymocytes from WT (solid gray) vs *chino* (red overlay) mice, representative of four separate experiments (n = 7 mice per group in total). (**G**) Histogram (left) and column graph (right, mean ± SEM) shows CD44 expression on CD4+ CD3+ B220− peripheral blood lymphocytes from littermate mice of the indicated *Mtor* genotypes, compiled from five separate experiments using a total of 20 *Mtor*^+/+^, 49 *Mtor*^+/*chi*^ and 7 *Mtor*^*chi/chi*^ mice. CD44 relative fluorescence intensity (RFI) was calculated by dividing by the mean for the *Mtor*^+/+^ group analyzed in the same experiment. Unpaired Student's *t* tests: \*\*\*p\<0.0001. (**H**) CD44 RFI on unstimulated CD4SP thymocytes of WT or *Rasgrp1*^*Anaef*^ mice after 7 days of treatment with the indicated rapamycin doses. Untreated control was set at 1. \*\*\*p\<0.005, n.s. = non significant.**DOI:** [http://dx.doi.org/10.7554/eLife.01020.015](10.7554/eLife.01020.015)10.7554/eLife.01020.016Figure 8---figure supplement 1.Alignment of HEAT5 domains in mTOR.Amino acid sequences of the indicated 13 species were aligned to demonstrate the level of conservation in the HEAT5 domain. Note the isoleucine residue in yellow that is altered by the *chino* mutation to serine.**DOI:** [http://dx.doi.org/10.7554/eLife.01020.016](10.7554/eLife.01020.016)

*Rasgrp1*^*Anaef*^ exaggerates basal mTOR-S6 signaling and CD44 expression in T cells {#s2-6}
-------------------------------------------------------------------------------------

Our finding that tonic CD44 expression on naïve T cells sensitively reports small changes in mTOR activity prompted further analysis of this pathway in *Rasgrp1*^*Anaef*^ T cells. CD44 was elevated on *Rasgrp1*^*Anaef*^ DP and SP thymocytes, in diametric contrast to decreased CD44 on these cells in *Rasgrp1*^*−/−*^ knockout mice ([Figure 9A,B](#fig9){ref-type="fig"}) ([@bib45]). A putative defect in regulatory T cells cannot explain the increased CD44 expression on naïve *Rasgrp1*^*Anaef*^ CD4^+^ cells, because in mixed chimeras bearing many wild-type Foxp3^+^ CD4 cells, CD44 expression was still increased on *Rasgrp1*^*Anaef*^ but not on co-resident wild-type CD62L^+^ FOXP3^−^ CD4^+^ splenocytes ([Figure 9C](#fig9){ref-type="fig"}). The cell autonomous increase in CD44 expression was detectable on *Rasgrp1*^*Anaef*^ SP and DP thymocytes ([Figure 9---figure supplement 1A,B](#fig9s1){ref-type="fig"}) and even on CD4^+^ cells expressing a transgenic TCR ([Figure 9D](#fig9){ref-type="fig"}). Elevated CD44 expression on *Rasgrp1*^*Anaef*^ cells was selective: there were no distinguishable differences between wildtype and *Rasgrp1*^*Anaef*^ cells in CD69 and TCRβ, which are markers of cumulative Ras signaling ([@bib13]; [@bib23]; [@bib61]), nor in CD5 expression, a sensitive reporter of TCR affinity and constitutive or tonic TCR signaling ([@bib6]; [@bib37]) ([Figure 9E](#fig9){ref-type="fig"}, [Figure 9---figure supplement 1A,B](#fig9s1){ref-type="fig"}), and rapamycin treatment in vivo selectively reduced the increased CD44 expression on *Rasgrp1*^*Anaef*^ cells ([Figure 8H](#fig8){ref-type="fig"}) but did not impact TCR or CD69 expression (data not shown).10.7554/eLife.01020.017Figure 9.Selective and cell-autonomous increase in CD44 expression in *Rasgrp1*^*Anaef*^ CD4+ T cells.(**A**) Representative CD44 expression on unstimulated CD4SP thymocytes from wildtype, *Rasgrp1*^*Anaef*^ and *Rasgrp1*^*−/−*^ mice. (**B**) Mean relative CD44 from 22 *Rasgrp1*^*Anaef*^, 13 wildtype, and 3 *Rasgrp1*^*−/−*^ mice compiled from seven experiments. In each experiment, the mean CD44 expression for the wildtype group was taken to be one, and values for individual mice were normalized to this. Unpaired Student's *t* tests were used to compare *Rasgrp1*^*Anaef*^ and *Rasgrp1*^*−/−*^ with the wildtype group. \*\*p\<0.005, \*\*\*p\<0.0005. (**C**) CD44 MFI on CD62L^+^Foxp3^−^CD4^+^ splenocytes from mixed bone marrow chimeras described in [Figure 7F](#fig7){ref-type="fig"}. Statistical comparisons used paired *t* tests within, and unpaired *t* tests between, groups of chimeras (n = 9 for both groups); \*\*\*p\<0.001, \*\*p\<0.01. (**D**) CD44 MFI on TCR3A9+ (clonotype positive) CD4^+^Foxp3^−^ splenocytes from B10.BR mixed bone marrow chimeras containing CD45.1^+^ wildtype TCR3A9 plus either CD45.2^+^ wildtype (n = 8) or CD45.2^+^ *Rasgrp1*^*Anaef*^ (n = 7) 3A9 TCR-transgenic hematopoietic cells. Statistical comparisons in (**C**) and (**D**) used paired *t* tests within groups of chimeras and unpaired *t* tests between groups of chimeras. p value symbols: \*\*\*p\<0.001, \*\*p\<0.01, \*p\<0.05. (**E**) *Rasgrp1*^*Anaef*^ increases CD44 expression levels but does not affect CD69 or CD5 expression. CD4SP thymocytes are analyzed from irradiated mice reconstituted with non-transgenic CD45.1^+^ wildtype mixed with CD45.2+ Rasgrp1^Anaef^ bone marrow.**DOI:** [http://dx.doi.org/10.7554/eLife.01020.017](10.7554/eLife.01020.017)10.7554/eLife.01020.018Figure 9---figure supplement 1.CD44 and P-S6 expression in thymocytes.(**A**) Selective effect of *Rasgrp1*^*Anaef*^ on CD44 expression during thymic maturation. Analysis of thymocytes from mixed chimeras (described in [Figure 9E](#fig9){ref-type="fig"}) bearing CD45.1^+^ WT (filled) plus CD45.2^+^ *Rasgrp1*^*Anaef*^ (black trace) hematopoietic cells. Histograms show CD44, CD69, CD5, TCRβ expression on DP, CD4SP and CD8SP thymocytes. (**B**) Column graph shows CD44 MFIs on CD45.1^+^ or CD45.2^+^ DP thymocytes from the mixed chimeras (in **A**) as well as control WT + WT chimeras (n = 5 mice per group). p value symbols for unpaired *t* tests between groups and paired *t* tests within groups: \*\*p: 0.01, \*p,: 0.05.**DOI:** [http://dx.doi.org/10.7554/eLife.01020.018](10.7554/eLife.01020.018)

Consistent with the CD44 data, P-S6 levels in unstimulated TCRβ^low^ (pre-selection) DP thymocytes were modestly increased in *Rasgrp1*^*Anaef*^ mice whereas they were decreased in cells from *Rasgrp1*^*−/−*^ mice ([Figure 10A](#fig10){ref-type="fig"}). CD44 levels gradually rise as T cells mature from DP to SP and peripheral naïve T cells, suggesting that CD44 expression may reflect basal or tonic signaling. Such signals can be visualized by constitutive tyrosine-phosphorylation of the TCRζ chains and other proteins ([@bib68]), basal levels of ZAP70 recruitment to phosphorylated zeta chains ([@bib67]; [@bib62]), and tonic phosphorylation of ERK ([@bib51]; [@bib38]). Furthermore, these signals dissipate when T cells are rested in vitro in non-stimulatory medium ([@bib68]; [@bib62]). We investigated tonic mTOR--S6 signals and found substantial basal P-S6 levels in freshly isolated lymph node cells that decreased when cells were serum-starved in vitro ([Figure 10B](#fig10){ref-type="fig"}). A recent study reported that naive CD4^+^ T cells display a range of CD5 expression in which the CD5^high^ cells receive most tonic signal input and are most immune reactive ([@bib37]). We first sorted CD44^low^ naïve CD4^+^ T cells into the most bright and most dim expression for CD5 and determined that CD5^high^ naïve CD4^+^ T cells have significantly more P-S6 than their CD5^low^ counterparts ([Figure 10C](#fig10){ref-type="fig"}). Next, dividing CD5^low^ and CD5^high^ naïve CD4^+^ T cells in equal 50--50% splits revealed that basal P-S6 was increased in *Rasgrp1*^*Anaef*^, particularly in the CD5^low^ subset compared to wildtype cells ([Figure 10D](#fig10){ref-type="fig"}). The exact origin of tonic signals in T cells and its function being either immune stimulatory or immune suppressive is still an area of debate ([@bib43]; [@bib59]; [@bib8]; [@bib62]; [@bib28]), but at least part of the tone appears to be generated by low affinity TCR binding to self pMHC ([@bib62]). To examine if self-peptide/MHCII recognition plays a role in the increased CD44 expression on *Rasgrp1*^*Anaef*^ naïve CD4^+^ T cells, we adoptively transferred a mixture of wild-type and *Rasgrp1*^*Anaef*^ splenocytes into wild-type or MHCII(*H2-Aa*)--deficient recipient mice ([Figure 10---figure supplement 1](#fig10s1){ref-type="fig"}). Maintenance of CD5 expression on T cells requires contact with self pMHC ([@bib59]; [@bib36]) and, as expected, CD5 expression on wildtype CD4^+^ CD62L^+^ Foxp3^−^ T cells decreased in MHCII-deficient hosts ([Figure 10E](#fig10){ref-type="fig"}), consistent with the hypothesis that CD5 is a sensitive reporter of TCR signal strength. By contrast, CD44 levels were similar irrespective of MHCII expression in the adoptive hosts, and CD44 levels remained higher on *Rasgrp1*^*Anaef*^ than co-transferred wild-type cells in both contexts ([Figure 10E](#fig10){ref-type="fig"}). These data reveal constitutively increased expression of two reporters of mTOR activity in *Rasgrp1*^*Anaef*^ naïve CD4^+^ T cells: the well-established reporter P-S6 and the reporter clarified here, CD44. The fact that the *Rasgrp1*^*Anaef*^--driven increase in CD44 is retained in the absence of MHCII suggests that this tonic signal is at least partially independent of triggering of TCRs by self-pMHC.10.7554/eLife.01020.019Figure 10.Increased tonic mTOR-S6 signals in *Rasgrp1*^*Anaef*^ thymocytes and T cells.(**A**) Tonic P-S6 levels in pre-selection DP thymocytes from wildtype, *Rasgrp1*^*Anaef*^ and *Rasgrp1*^*−/−*^ mice. Representative histograms are shown for five independent experiments with n = 9 for WT, n = 7 for *Rasgrp1*^*Anaef*^ and n = 7 *Rasgrp1*^*−/−*^ mice. (**B**) Total lymph node cells were analyzed for the indicated phospho-proteins either immediately after extraction and single cell suspension generation (0') or after a 30 min rest period in PBS at 37° (30'). (**C**, **D**) Western blot measurements of basal P-S6 and P-ERK in unstimulated naive CD4^+^CD44^lo^ T cells sorted into CD5^low^ and CD5^high^ subsets from wildtype and *Rasgrp1*^*Anaef*^ mice. Equal loading was confirmed with specific blotting for ERK2, which can be done without stripping. Panels c-e are representative results of at least three independent experiments. (**E**) CD45.1 wild-type and *Rasgrp1*^*Anaef*^ splenocytes were mixed, labeled with CellTrace Violet and adoptively transferred into CD45.2 wild-type or MHCII--deficient recipient mice ([Figure 10---figure supplement 1](#fig10s1){ref-type="fig"}). 48 hr later, donor-derived CD4^+^CD62L^+^FOXP3^−^ cells in recipient spleens were resolved by flow cytometry and their CD44 (upper panel) and CD5 (lower panel) MFIs were plotted. Lines connect measurements from individual mice.**DOI:** [http://dx.doi.org/10.7554/eLife.01020.019](10.7554/eLife.01020.019)10.7554/eLife.01020.020Figure 10---figure supplement 1.Testing the role of MHCII recognition in constitutive CD44 overexpression by *Rasgrp1*^*Anaef*^ naive CD4 T cells.Schematic of experiment design as described in the text (top) and flow cytometric resolution of co-transferred (CTV^+^) donor WT (CD45^1/1^) and *Rasgrp1*^*Anaef*^ (CD45^2/2^) naive CD4 T cells on which CD5 and CD44 expression were compared (bottom).**DOI:** [http://dx.doi.org/10.7554/eLife.01020.020](10.7554/eLife.01020.020)

CD44^+^ Helios^+^ PD-1^+^ CD4^+^ T cell accumulation and autoantibodies in *Rasgrp1*^*Anaef*^ mice are corrected by hypomorphic mTOR mutation {#s2-7}
---------------------------------------------------------------------------------------------------------------------------------------------

To test the role of elevated mTOR signaling in the *Rasgrp1*^*Anaef*^--induced overexpression of CD44 in naïve T cells and in the accumulation of activated CD44^hi^ PD-1^+^ CD4^+^ cells and autoantibodies, *Rasgrp1*^*Anaef*^ mice were intercrossed with the subtle loss-of-function *Mtor*^*chino*^ strain. Using a CD62L^+^ Foxp3^−^ gate to resolve naïve CD4^+^ splenocytes, we found that the *Mtor*^*chino*^ mutation abolished the *Rasgrp1*^*Anaef*^--driven increase in CD44 expression in these naïve T cells ([Figure 11A](#fig11){ref-type="fig"}). The *Mtor*^*chino*^ mutation alone resulted in a decrease in numbers of splenocytes, including CD4^+^ cells, as was observed in mice with reduced *Mtor* mRNA ([@bib74]), but the relative proportions of the CD4^+^ subsets examined were normal ([Figure 11B](#fig11){ref-type="fig"}). Whereas *Rasgrp1*^*Anaef*^ mice with normal mTOR accumulated a high frequency of CD44^hi^ Foxp3^−^ CD4^+^ splenocytes, including the prominent PD-1^+^ Helios^+^ subset, this was corrected down to normal numbers in *Rasgrp1*^*Anaef*^ *Mtor*^*chino*^ double mutants ([Figure 11B,C](#fig11){ref-type="fig"}). Moreover, in bone marrow chimeras bearing *Rasgrp1*^*Anaef*^ *Mtor*^*chino*^ double-mutant hematopoietic cells, the frequency of animals with antinuclear autoantibodies was corrected to the low frequency observed in control chimeras with wildtype *Rasgrp1* and *Mtor* ([Figure 11D](#fig11){ref-type="fig"}). Collectively, these results establish that accumulation of CD44^hi^ Helios^+^ PD-1^+^ CD4^+^ cells and autoantibodies induced by *Rasgrp1*^*Anaef*^ is sensitive to small differences in mTOR signaling.10.7554/eLife.01020.021Figure 11.*Mtor* hypomorphic mutation corrects *Rasgrp1*^*Anaef*^--induced increase in naive T-cell CD44 expression and accumulation of CD44^+^Helios+PD-1^+^CD4^+^ cells and autoantibodies.(**A**) *B6.Rasgrp1*^*Anaef*^ mice were intercrossed with *B6.Mtor*^*chino*^ mice to generate the single and double-mutant mice. Representative CD44 histograms of CD62L^+^FOXP3^−^CD4^+^ splenocytes from these *chino*, *Anaef*, and *Anaef.chino* mutants were overlaid against wild-type cells and plotted. Below, CD44 MFI of mice was normalized against average CD44 MFI of wild-type mice across two independent experiments and graphed, with columns showing mean ± SEM. Significance indicated using a 1-way ANOVA and Tukey's post-test at n = 13 WT, 5 *chino*, 15 *Anaef*, and 4 *Anaef.chino*. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001. (**B**) Representative CD44 vs FOXP3 plots for these four genotypes from (**A**), which display CD4^+^ splenocytes gated into naïve (CD44^lo^ FOXP3^−^), activated/memory (CD44^hi^ FOXP3^−^), and T-reg (FOXP3^+^) populations. Absolute numbers of these three subsets across all four genotypes is graphed below, with columns showing mean ± SEM. Significance indicated using a 1-way ANOVA and Tukey's post-test at n = 13 WT, 5 *chino*, 15 *Anaef*, and 4 *Anaef.chino*. \*p\<0.05, \*\*p\<0.01. (**C**) Bone marrow cells from sibling mice described in (**A**) and (**B**) were used to reconstitute irradiated *B6.SJL CD45*^*1/1*^ mice, which were analyzed 28 weeks after irradiation. Plots show HELIOS vs PD-1 expression on FOXP3^−^ CD4^+^ splenocytes, representative of both nonchimeric and chimeric mice. Absolute number of HELIOS^+^ PD-1^+^ FOXP3^−^ CD4^+^ splenocytes per mouse is graphed below, with columns showing mean ± SEM. Significance indicated using a 1-way ANOVA and Tukey's post-test at n = 11 WT, 10 *chino*, 10 *Anaef*, 11 *Anaef.chino*. \*\*\*p\<0.001. (**D**) Chimeric mice from (**C**) were bled 27 weeks after irradiation and the presence of homogeneous nuclear ANA in blood plasma was measured by immunofluorescence on HEp-2 cells and scored in a blinded manner.**DOI:** [http://dx.doi.org/10.7554/eLife.01020.021](10.7554/eLife.01020.021)

Discussion {#s3}
==========

The findings here reveal a new role for Rasgrp1 in the cell-intrinsic regulation of peripheral CD4^+^ T cells. By analyzing a missense mutation in the Rasgrp1 EF-hand, the results dissociate this new function of Rasgrp1 from its well-known role in thymic positive selection. While the *Anaef* EF-hand mutation did decrease Rasgrp1 activation of Ras and ERK when thymocytes were stimulated acutely by antibodies to CD3 or with PMA in vitro, the activity of this pathway during physiological positive selection in vivo remained sufficient for normal numbers of single positive thymocytes and peripheral T cells to form even under competitive reconstitution conditions. T cell lymphopenia and sparse T cell repertoires secondary to defective positive selection potentially explain the autoantibodies observed in mice where Rasgrp1 is entirely absent or C-terminally deleted ([@bib17]; [@bib12]; [@bib45]; [@bib21]), and in animals with missense mutations in ZAP-70 or LAT ([@bib3]; [@bib60]; [@bib55]; [@bib57]). By contrast, the normal thymic development coupled with experiments in mixed bone marrow chimeras where wild-type and mutant T cells co-exist rules out this possibility for the *Rasgrp1*^*Anaef*^ mutation, and shows that peripheral CD4 cells are intrinsically dysregulated. By a combination of biochemical and genetic studies, we identify overactive mTOR signaling within naïve CD4 T cells as a key component for *Rasgrp1*^*Anaef*^ to drive two abnormalities: (1) a constitutive increase in CD44 expression in naïve CD4 T cells and (2) a gradual accumulation of peripheral Helios^+^ CD44^hi^ CD4 cells and autoantibodies.

*Rasgrp1*^*Anaef*^'s effect on Ras/ERK signaling in vivo was much milder than expected from its effects in *in vitro* assays. In response to relatively strong in vitro stimuli, the *Rasgrp1*^*Anaef*^ mutation results in impaired membrane recruitment and T~184~ phosphorylation of Rasgrp1 as well as reduced activation of Ras-ERK, establishing that *Rasgrp1*^*Anaef*^ is a hypomorphic (partial loss-of-function) allele under these conditions. By contrast, in vivo, *Rasgrp1*^*Anaef*^ did not alter CD69 and TCRβ induction or positive selection of thymocytes, unlike the C-terminally deleted (*Rasgrp1*^*d/d*^) and knockout (*Rasgrp1*^−/−^) alleles which caused moderate and severe decreases in these processes, respectively. This may indicate that the cumulative Ras-ERK signals required for these events are sufficiently buffered or robust that they tolerate a modest reduction in Rasgrp1's Ras activating activity. Only when a TCR transgene was prematurely expressed at higher than normal levels in DP thymocytes was there a measurable deficit in positive selection, and even under these conditions there was a small decrease in positive selection compared even to the subtle *Zap70*^*murdock*^ mutation ([@bib57]). This is surprising given that the induction of these signals involves low affinity pMHC binding by the TCR, which might be expected to be particularly sensitive to small changes in Ras-ERK signal strength ([@bib35]).

CD44 expression on thymocytes is decreased in the complete absence of Rasgrp1 ([Figure 9](#fig9){ref-type="fig"}) ([@bib45]) and increased by oncogenic Ras ([@bib33]; [@bib73]; [@bib69]) establishing that CD44 expression in thymocytes is positively regulated by Ras. T-cell CD44 expression is also sensitive to mTOR activity, being reduced by the partial loss-of-function *Mtor*^*chino*^ ([Figure 8](#fig8){ref-type="fig"}) and *Mtor*^*tm1Lgm*^ ([@bib74]) alleles, and dramatically decreased in the absence of Rictor ([@bib16]), a binding partner of mTOR. *Rasgrp1*^*Anaef*^ thymocytes and naïve CD4 T cells have increased CD44 and P-S6 expression, suggesting that the *Anaef* mutation increases either Rasgrp1/Ras/ERK signaling or PI-3-kinase/mTOR/S6 signaling, or both. Our recent biophysical studies revealed that Rasgrp1's EF hands keep the protein in an autoinhibited, dimeric state, and modeling indicates that calcium-binding to the EF domain would relieve autoinhibition ([@bib30]). Thus, Rasgrp1's EF hands play both stimulatory- and inhibitory-roles that may result in the EF2 substitution in *Rasgrp1*^*Anaef*^ decreasing maintenance of the autoinhibited state in the absence of strong TCR stimuli and decreasing RasGRP1 activation during strong TCR stimulation. Evidence exists for multiple intersections between the RasGRP1/Ras/ERK/RSK and PI-3-kinase/mTOR/S6 pathways, including at the level of Ras with PI-3-kinase ([@bib10]) and at the level of RSK with S6 ([@bib56]). While the mechanism is currently unclear, the current evidence suggests that *Rasgrp1*^*Anaef*^'s gain-of-function in naïve T cells in the absence of strong TCR stimulation--and apparently in the absence of MHCII ligands for the TCR ([Figure 10E](#fig10){ref-type="fig"})---activates S6-CD44 more than it activates ERK-CD69.

In T cells, the mTOR pathway is activated by strong TCR stimulation ([@bib26]) and is required for efficient differentiation of naïve CD4 cells into effector cells ([@bib15]). T-cell-specific deletion of Tsc1, a negative regulator of mTOR, results in increased levels of P-S6 and an exuberant response to TCR stimulation in naïve T cells ([@bib71]). Increased mTOR stimulation by Rasgrp1^Anaef^ may allow self-antigens to activate some naïve CD4 cells, resulting in the gradual accumulation of activated CD62L^low^ CD44^hi^ PD-1^+^ HELIOS^+^ T cells and antinuclear autoantibodies. Because accumulation of PD-1^+^ HELIOS^+^ T cells in *Rasgrp1*^*Anaef*^ mice requires B cells ([Figure 7](#fig7){ref-type="fig"}), these T cells might require B cells as specialized APCs or they might require Fc receptor-dependent enhancement of antigen presentation by antibodies ([@bib58]).

Given the huge number of missense variants in each person ([@bib77]), patients with autoimmune diseases are more likely to have point mutations in various genes than complete loss of gene expression. This new *Rasgrp1*^*Anaef*^ mouse model adds to an emerging category of animal models with point mutations in TCR signaling proteins, along with *Zap70*^*skg*^ ([@bib55]), *Zap70*^*murdock*^ and *Zap70*^*mrtless*^ hypomorphic alleles ([@bib57]), LAT^Y136F^ mice ([@bib3]; [@bib60]), and *Card11*^*unmodulated*^ mice ([@bib31]), where a partial deficit in T cell signaling precipitates autoimmunity or allergy. *RASGRP1* splice variants have been documented for patients with SLE ([@bib72]) and abnormal microRNA-driven downregulation of Rasgrp1 expression may play a role in aberrant DNA methylation in Lupus CD4^+^ T cells ([@bib41]). In addition, *RASGRP1*-linked SNVs have been associated with autoimmune diabetes and thyroid disease ([@bib47]; [@bib42]). Of the 13 uncharacterized *RASGRP1* missense SNVs currently known, rs62621817 is of particular interest here since it causes a missense variation in RasGRP1's first EF hand, changing a conserved, negatively charged aspartic acid into a valine residue. We propose that *Rasgrp1*^*Anaef*^ mice may provide a useful model system for further studies to help elucidate how *RASGRP1* variants contribute to autoimmune disease, and to help target future efforts to modulate this pathway pharmacologically.

Materials and methods {#s4}
=====================

Mice {#s4-1}
----

Mice were housed in pathogen-free conditions and experiments approved by either the Australian National University Animal Ethics and Experimentation Committee (Goodnow group, A2011/46) or the Institutional Animal Care and Use Committee of the University of California, San Francisco (Roose group, AN084051-01). C57BL/6 (B6), C57BL/6.SJL (CD45.1), B10Br, B10Br.CD45.1, B10Br TCR^3A9^, *Cd79a*^*null*^ (also called *Cd79a*^m1ANU^) and MHCII-deficient (*H2-Aa*^tm1Blt^) mice were obtained from ANU Bioscience Services. The *Rasgrp1*^*Anaef*^ and *Mtor*^*chino*^ strains were established through ethylnitrosourea (ENU)-mediated mutagenesis of B6 mice at the Australian National University as previously described ([@bib50]).

Genetic mapping of the *Anaef* mutation {#s4-2}
---------------------------------------

Affected Rasgrp1^*Anaef*^ mice were crossed onto the CBA/J background to generate heterozygous F1 mice. F1 mice were intercrossed to yield mice homozygous for the *Anaef* mutation and carrying a mix of C57BL/6 and background CBA/J single nucleotide polymorphisms (SNPs). Genomic DNA samples isolated from both affected and unaffected mice were used as templates for SNP mapping at the Genomics Institute of the Novartis Research Foundation (San Diego, CA). SNP markers were spaced approximately every 3--5 Mbp throughout the genome. Once a defined interval was established, the Rasgrp1 encoding gene was sequenced from genomic DNA from both affected *Anaef* and WT mice. All exons were amplified by PCR with primers designed to include intronic RNA splice donor and acceptor sites. Exome enrichment using the SureSelect Mouse Exome kit (G7550A-001; Agilent, Santa Clara, CA), sequencing using the Illumina HiSeq 2000 (Illumina, San Diego, CA), and computational analysis to detect novel single-nucleotide variants were performed as described previously ([@bib4]).

Genotyping {#s4-3}
----------

Roose lab *Anaef* mice were genotyped using MS-PCR. Primers were combined in a single reaction with Taq, Taq buffer and dNTPs (all New England BioLabs, Ipswich, MA). Goodnow lab *Anaef* mice were genotyped by APF Genomics Services following the manufacturer's instructions for Amplifluor PCR (SNP FAM/JOE; Millipore, Billerica, MA).

Transfections and stable cell lines {#s4-4}
-----------------------------------

Transfections and creation of stable cell lines was performed as previously described ([@bib52]).

Antinuclear antibody testing {#s4-5}
----------------------------

Diluted mouse plasma was applied to HEp-2 slides (Inova, San Diego, CA). AlexaFluor488-conjugated goat anti-mouse IgG (Invitrogen, Carlsbad, CA) was added and slides mounted with fluorescence mounting medium (Dako Australia). Photos were taken using an Olympus IX71 microscope and WIB filter with 20 × lens and exposure time of 1/25 s.

Flow cytometry {#s4-6}
--------------

Suspensions of splenocytes (depleted of erythrocytes by brief osmotic lysis) or thymocytes were incubated with cocktails of anti-mouse antibodies specific for: CD44, CD4, CD45.1, CD45.2, CD5, CD62L, CD69, TCRβ, PD-1, TCR Vβ5, TCR Vβ8, TCR Vβ11, B220, CD95, GL-7, B220 (BD Pharmingen Franklin Lakes, NJ or BioLegend San Diego, CA) or CD8 (BD Pharmingen and UCSF Monoclonal Antibody Core, clone YTS169.4) conjugated to AlexaFluor700, APC-780 or APCCy7, PE-Cy7, APC, PerCPCy5.5, FITC, PE, Pacific Blue or biotin. Biotinylated antibodies were detected in another incubation step with streptavidin conjugated to Qdot605 (Invitrogen) or BV605 (BioLegend). Cells expressing the 3A9 TCR transgene were detected using the 1G12 (mouse IgG1) antibody (ATCC, Manassas, VA) followed by another incubation in anti-mouseIgG1 (A85.1). To detect intracellular proteins, cells were fixed and permeabilized using a Foxp3 staining kit (eBioscience, San Diego, CA), then labeled with antibodies specific for Foxp3 (FJK-16s; eBioscience), Helios (clone 22F6; Biolegend), IFNγ, IL-4, IL-2 or IL-17 (all BD Pharmingen). Flow cytometry data was acquired on a FACSort (Becton Dickinson) or an LSR Fortessa system and analyzed with FlowJo v8 (Treestar, Ashland, OR).

Cell stimulations {#s4-7}
-----------------

Cells were stimulated using 25 ng/ml (HIGH), 5 ng/ml (MED), or 2 ng/ml (LOW) PMA (Calbiochem) with/without ionomycin (10 μM, Sigma, St. Louis, MO), or with 100 ng/ml PMA for Phospho-S6 assays. To mimic TCR engagement, cells were pre-labeled using anti-CD3 primary antibody (10 μg/ml, UCSF Monoclonal Antibody Core, clone 2C11) and crosslinking was achieved using goat anti-hamster antibody (10 μg/ml, Jackson ImmunoResearch). For intracellular cytokine detection by flow cytometry, splenocytes were stimulated in complete medium for 4 hr at 37°C with PMA (100 ng/ml; Sigma), ionomycin (500 ng/ml; Sigma) and GolgiStop (1/1000; BD), then labeled as described above.

Flow cytometry for phosphorylated proteins {#s4-8}
------------------------------------------

Procedure was performed as described in [@bib14]. Cells were fixed using Cytofix Cell Fixative (BD Biosciences). Cells were permeabilized using 90% Methanol. Primary staining for phospho-Erk occurred using rabbit anti-mouse p-Erk antibody (\#4377S; Cell Signaling) followed by staining with goat anti-Rabbit PE (Jackson ImmunoResearch, West Grove, PA). For analysis of tonic and PMA induced S6 phosphorylation by FACS, single-cell suspensions were prepared from thymus. Half of the cells were fixed in warm cytofix (BD Biosciences) immediately after harvesting and reserved for tonic signaling analysis. The remaining cells were then counted, and 10^6^ cells/sample were stimulated with PMA for 3 min, followed by fixation. Stimulated and unstimulated cells were then washed three times with cytoperm buffer (BD Biosciences) and incubated on ice in this buffer with a rabbit polyclonal antibody against phosphorylated S6 (cell signaling) for 45 min. The cells were then washed twice with cytoperm and incubated for an additional 45 min in cytoperm buffer containing an APC-conjugated goat anti-rabbit secondary antibody, as well as anti CD8-FITC, CD4, PE-Cy7 and TCRβ-PE. Cells were washed twice and analyzed in an LSR Fortessa system.

Ras pulldown {#s4-9}
------------

Activation of Ras was analyzed using a RasGTP pulldown assay (Upstate Biotechnology, Lake Placid, NY) as previously described ([@bib52]).

Western blotting {#s4-10}
----------------

Cells were lysed using Nonidet-P40 lysis buffer (1%) supplemented with protease and phosphatase inhibitors. Lysates were run on 10% acrylamide Bis-Tris gels and transferred onto PDVF filter (Millipore, Immobilon-P). Blots were probed for Rasgrp1 (M199; Santa Cruz, Dallas, TX), Alpha tubulin (Sigma), phospho-tyrosine (In house antibody prep, clone 4G10), phospho-Zap70 (Y493; Cell Signaling, Danvers, MA), phospho-PLCγ (Y783; Cell Signaling) and phospho-Lck (Y416; Cell Signaling), anti-ERK (pan-Erk) antibody (BD Transduction labs, clone 16/ERK). Rabbit anti-human Rasgrp1 (clone E80) was produced by Epitomics, Inc. (Burlingame, CA, USA). Mouse anti-Rasgrp1 p-T184 (clone JR-pT184RG1-4G7) was produced by AnaSpec (Fremont, CA, USA). Signal from primary antibodies detected using HRP conjugated secondary antibodies: Sheep anti-mouse HRP (GE Healthcare, Cleveland, OH) and goat anti-rabbit HRP (SouthernBiotech, Birmingham, AL). Blots were developed using Pierce ECL Western Blotting Substrate (ThermoScientific, Waltham, MA) and images recorded using a chemiluminescence imager (LAS-4000; Fuji).

Bone marrow chimeras {#s4-11}
--------------------

Bone marrow was collected, and in some experiments, depleted of T cells and NK cells by magnetic labelling using biotinylated anti-TCRβ and anti-NK1.1 and streptavidin microbeads followed by passage through a MACS LD column (Miltenyi Biotec, Germany). Recipient mice were irradiated with X-rays (2 doses of 4.5 Gy given 4 hr apart) then injected intravenously (i.v.) with 2 × 10^6^ bone marrow cells that were either from single or multiple donors as described in the text.

Rapamycin treatment {#s4-12}
-------------------

Suboptimal doses of rapamycin ([@bib11]; [@bib5]) were prepared on day 0 in sufficient quantity for all injections in one experiment. The appropriate rapamycin stock volume was diluted to the indicated concentrations in DMSO (15.4%), Cremaphor (15.4%) and water (69.2%), and aliquoted in six equal portions (one aliquot per injection) and frozen. Mice were injected on days 0, 1, 2, 3, 5 and 7, and then sacrificed on day 8. Thymocytes were harvested and analyzed as before.

BrdU labelling {#s4-13}
--------------

1 mg BrdU (BD) in PBS per mouse was injected i.p. to pulse label a cohort of dividing cells. Following surface staining of thymocytes as above, BrdU was detected following the BrdU Flow Kit (BD) protocol by fixing and permeabilizing cells with provided buffers, incubating for 1 hr at 37°C in DNase, then washing and staining with anti-BrdU antibody.

CellTrace Violet (CTV) labelling {#s4-14}
--------------------------------

CTV labeling was done at room temperature as described ([@bib48]) with slight modifications. Splenocytes suspended at 10^8^ cells/ml in RPMI containing HI-FCS (10% vol/vol) were transferred to the base of a fresh 15 ml conical tube. 1 µl of CTV (Life Technologies, Carlsbad, CA) stock solution (10 mM) per ml of cell suspension was placed on the dry wall of the tubes, then tubes were capped, inverted and briefly vortexed (final CTV concentration 10 µM). After 5 min incubation in the dark, 10 ml of 10%FCS/RPMI was added, then cells were sedimented by centrifugation before another wash in 10 ml of the same medium. Cells were then resuspended in PBS and passed through a 70 µm cell strainer (BD) before i.v. injection (200 µl per mouse).
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Thank you for sending your work entitled "A missense variant of *Rasgrp1* increases tonic mTOR signals resulting in aberrant helper T cells and autoantibodies" for consideration at *eLife*. Your article has been favorably evaluated by a Senior editor and 3 reviewers, one of whom is a member of our Board of Reviewing Editors, and one of whom, Jonathan Powell, has agreed to reveal his identity.

The Reviewing editor and the other reviewers discussed their comments before we reached this decision, and the Reviewing editor has assembled the following comments to help you prepare a revised submission.

1\) It seems likely that the *Rasgrp1*^*Anaef*^ mutation results in the loss of function of the molecules by a dominant negative effect and reduced expression of *Rasgrp1* ([Figure 2](#fig2){ref-type="fig"} and [Figure 4](#fig4){ref-type="fig"}). However, the mutation enhanced CD44 expression, which is apparently opposite to the phenotype of *Rasgrp1*^*null*^ mutation. While the authors claim that a slight difference in mTOR-CD44 pathway would be responsible for the phenotypic difference, more precise analysis is required for addressing the difference. Similarly, tonic mTOR activation and reduced ERK signaling do not link to the observed effects, such as the increase of anti-nuclear antibodies and the accumulation of a CD44^hi^ T cells. In addition, with the finding that CD44, Helios, PD-1, CXCR5, Foxp3 and IFNg were upregulated in *Rasgrp1*^*Anaef*^ mice, can these phenotypes also be explained by the slight change of mTOR and the inhibition of ERK? Are there any common mechanisms for the regulation of these genes? Why does a fraction of CD4^+^ T cells remain CD44^lo^ ? Are those cells expressing a peculiar phenotype when compared to the CD44^hi^ CD4^+^ T cells?

2\) Although the mutant mice showed significant reduction of the ERK signaling, the authors concluded that there were no abnormalities in CD4SP thymocytes, regulatory T cells, and clonal deletion. The authors need to examine whether their functions, such as suppressive activity of regulatory T cells, are normal.

3\) In [Figure 5A](#fig5){ref-type="fig"}, the reduced levels of P-T184 in the Rasgrp1^Anaef^ thymocytes may be due to the reduced levels of Rasgrp1^Anaef^ protein and to the poor stability of Rasgrp1^Anaef^ following TCR stimulation. To dismiss this possibility, the blot needs to be immune-blotted with an anti-Rasgrp1 antibody (as shown in [Figure 2E](#fig2){ref-type="fig"}). In addition, the *Rasgrp1*^*Anaef*^ mutation could be more similar to the *Rasgrp1*^*null*^ mutation compared with the *Rasgrp1*^*+/-*^ mutation. To compare functional differences, it is recommended to include the *Rasgrp1*^*null*^ mutation in [Figure 5](#fig5){ref-type="fig"}.

4\) In [Figure 10](#fig10){ref-type="fig"}, the data suggesting that "substantial" levels of P-S6 are found in freshly isolated lymph nodes need to be shown.

5\) The conclusion that tonic TCR signal results in basal mTOR-S6 needs to be further substantiated since it is based on the aggregation of disparate data from the Germain laboratory and from the authors' laboratory.

6\) To identify the mutated gene, the authors narrowed down the region where the mutation located and picked up *Rasgrp1* because it was the only gene with an immune function within the located region. As some phenotypes were different between *Rasgap1*^*null*^ and *Rasgap1*^*Anaef*^ mutation, is there a possibility that another mutation locating on the adjacent region is involved in the observed phenotypes? In this context, if the progeny is generated from *Rasgrp1*^*Anaef*^ mice that are ANA negative ([Figure 1D](#fig1){ref-type="fig"}), are they ANA positive?

7\) It might be interesting if the authors quickly review papers that have genetically deleted mTOR signaling in T cells to see if there might be differences in CD44 expression in those mice that might not have been emphasized in the original papers.
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Author response

*1) It seems likely that the* Rasgrp1^Anaef^ *mutation results in the loss of function of the molecules by a dominant negative effect and reduced expression of Rasgrp1 (*[*Figure 2*](#fig2){ref-type="fig"} *and* [*Figure 4*](#fig4){ref-type="fig"}*). However, the mutation enhanced CD44 expression, which is apparently opposite to the phenotype of* Rasgrp1^null^ *mutation. While the authors claim that a slight difference in mTOR-CD44 pathway would be responsible for the phenotypic difference, more precise analysis is required for addressing the difference. Similarly, tonic mTOR activation and reduced ERK signaling do not link to the observed effects, such as the increase of anti-nuclear antibodies and the accumulation of a CD44*^*hi*^ *T cells. In addition, with the finding that CD44, Helios, PD-1, CXCR5, Foxp3 and IFNg were upregulated in* Rasgrp1^Anaef^ *mice, can these phenotypes also be explained by the slight change of mTOR and the inhibition of ERK? Are there any common mechanisms for the regulation of these genes? Why does a fraction of CD4*^*+*^ *T cells remain CD44*^*lo*^ *? Are those cells expressing a peculiar phenotype when compared to the CD44*^*hi*^ *CD4*^*+*^ *T cells*?

We apologize for not being clear about the various consequences of the Anaef mutation in the original manuscript. We have made a number of changes to clarify the evidence that the Anaef mutation has 2 distinct effects: (1) it increases naïve T-cell CD44 expression and (2) it drives accumulation of CD44^hi^ effector CD4^+^ T cells and autoantibodies.

To distinguish between effects (1) and (2) above, new or modified figure panels demonstrate that *Rasgrp1*^*Anaef*^ increases CD44 expression in naïve T cells even in heterozygous *Rasgrp1*^*Anaef/+*^ mice (new [Figure 1B](#fig1){ref-type="fig"}), in the absence of B cells (new [Figure 7C and 7E](#fig7){ref-type="fig"}) or in the absence of MHCII expression (new [Figure 10E](#fig10){ref-type="fig"}), in the presence of large numbers of wildtype Treg cells in mixed chimeras (new [Figure 9C](#fig9){ref-type="fig"}) and increased CD44 levels are detectable even at the DP stage of thymocyte development (new [Figure 9B](#fig9){ref-type="fig"} and Figure 9--figure supplement 7B). The opposite effects of the null and Anaef alleles on CD44 expression in CD4SP thymocytes suggest that Anaef is in fact a gain-of-function allele under steady-state conditions in vivo. Rasgrp1's autoinhibitory homodimer conformation recently published in *eLife* (Iwig et al.) offers an explanation for this: in the absence of calcium, the second EF hand (mutated in Anaef) conceals the DAG-binding C1 domain on the opposing monomer. We now cite papers that demonstrate intersections between the Ras and mTOR signaling pathways and conclude that, although the mechanism is unclear, Rasgrp1^Anaef^'s gain-of-function activates the mTOR pathway more strongly than it activates the ERK pathway.

The immediacy of effect (1) contrasts with the gradual, age-dependent nature of effect (2), i.e., accumulation of CD44^hi^ CD4^+^ T cells ([Figure 6C](#fig6){ref-type="fig"}). These 2 effects are also separable in that only effect (2) requires B cells ([Figure 7](#fig7){ref-type="fig"} with new panel 7D). Importantly, both effects are rectified by the reduction-of-function *Mtor*^*chino*^ mutation ([Figure 11A-D](#fig11){ref-type="fig"} with new panel 11A), demonstrating a central role for mTOR.

Thanks to the constructive criticism we received, we believe that the changes underlined in our revised Title, Abstract, Introduction, Results, and Discussion help to explain our data more clearly, and offer testable hypotheses for the underlying mechanisms.

*2) Although the mutant mice showed significant reduction of the ERK signaling, the authors concluded that there were no abnormalities in CD4SP thymocytes, regulatory T cells, and clonal deletion. The authors need to examine whether their functions, such as suppressive activity of regulatory T cells, are normal*.

We have clarified in text in the Discussion that although we do not observe any deficit in frequency of Foxp3^+^ Tregs, we have not tested if these Tregs have normal suppressive activity. We do conclude that should any deficit in Treg suppressive activity exist, it does not account for the increased CD44 on naïve CD4s nor the increased formation of CD4 effectors, because those abnormalities are cell autonomous and not corrected in mixed chimeras where there are large numbers of wildtype Tregs. The following text has been added:

"A putative defect in regulatory T cells cannot explain the increased CD44 expression on naïve *Rasgrp1*^*Anaef*^ CD4^+^ cells, because in mixed chimeras bearing many wild-type Foxp3^+^ CD4 cells, CD44 expression was still increased on *Rasgrp1*^*Anaef*^ but not on co-resident wild-type CD62L^+^ FOXP3^--^ CD4^+^ splenocytes."

*3) In* [*Figure 5A*](#fig5){ref-type="fig"}*, the reduced levels of P-T184 in the Rasgrp1*^*Anaef*^ *thymocytes may be due to the reduced levels of Rasgrp1*^*Anaef*^ *protein and to the poor stability of Rasgrp1*^*Anaef*^ *following TCR stimulation. To dismiss this possibility, the blot needs to be immune-blotted with an anti-Rasgrp1 antibody (as shown in* [*Figure 2E*](#fig2){ref-type="fig"}*). In addition, the* Rasgrp1^Anaef^ *mutation could be more similar to the* Rasgrp1^null^ *mutation compared with the* Rasgrp1^+/-^ *mutation. To compare functional differences, it is recommended to include the* Rasgrp1^null^ *mutation in* [*Figure 5*](#fig5){ref-type="fig"}.

We agree with this point. Indeed the total Rasgrp1 expression levels that accompany [Figure 5A](#fig5){ref-type="fig"} (and 5B) were shown in supplemental figure S4c of the original manuscript, and these immunoblots demonstrate that the loss of T184 phosphorylation is not due to the decreased expression of total Rasgrp1. For the sake of clarity we have now eliminated that figure and included all the controls in [Figures 5A and 5B](#fig5){ref-type="fig"}.

Regarding direct comparisons with Rasgrp1 null thymocytes, TCR-induced ERK activation is severely impaired in Rasgrp1 null thymocytes and this has been published (e.g., Dower et al., *Nature Immunology*). Since Rasgrp1 deficiency results in a severe block in thymocyte development, Rasgrp1 null thymi consist almost entirely of CD4CD8 double positive thymocytes with low levels of TCR expression. There are virtually no CD4 or CD8 single positive cells that are more mature and express higher levels of surface TCR. Very differently, WT of Rasgrp1^Anaef^ thymi contain all normal thymocyte populations. Functional comparisons of TCR-induced PLCgamma and ERK activation in Rasgrp1^Anaef^ (or WT) thymocytes with the signals in Rasgrp1^null^ thymocytes are not very informative (and perhaps even confusing for the reader) since these comparisons involve not only different developmental thymocyte subsets but also have the caveat of comparing cells with different levels of TCR expression, which is known to affect the efficiency of TCR stimulation.

*4) In* [*Figure 10*](#fig10){ref-type="fig"}*, the data suggesting that "substantial" levels of P-S6 are found in freshly isolated lymph nodes need to be shown*.

We thank the reviewers for this suggestion -- these data have now been added as new [Figure 10B](#fig10){ref-type="fig"}, which shows immunoblots of extracts from lymph node cells before or after a 30 minute PBS rest, and probing for total phospho-tyrosine, pZap70, pErk, and pS6. The blots clearly demonstrate that phosphorylated signaling molecules, including S6, are readily detectable in freshly isolated samples and that these levels decrease upon brief resting in PBS. We also moved a panel from the supplement to become new [Figure 10C](#fig10){ref-type="fig"}, which shows tonic S6 signals in purified CD4 T cells.

*5) The conclusion that tonic TCR signal results in basal mTOR-S6 needs to be further substantiated since it is based on the aggregation of disparate data from the Germain laboratory and from the authors' laboratory*.

We thank the reviewers for this important query. We performed an experiment to test the role of self- peptide/MHCII recognition, and found that the elevated CD44 levels on naïve CD4 T cells from the Anaef mice is retained when cells are transferred into MHCII knockout mice These results are presented in new [Figure 10E](#fig10){ref-type="fig"}. Therefore we inserted the following text into the Results:

"To examine if self-peptide/MHCII recognition plays a role in the increased CD44 expression on *Rasgrp1*^*Anaef*^ naïve CD4^+^ T cells, we adoptively transferred a mixture of wild-type and *Rasgrp1*^*Anaef*^ splenocytes into wild-type or MHCII(*H2-Aa*)--deficient recipient mice..."

*6) To identify the mutated gene, the authors narrowed down the region where the mutation located and picked up* Rasgrp1 *because it was an only gene with an immune function within the located region. As some phenotypes were different between* Rasgap1^null^ *and* Rasgap1^Anaef^ *mutation, is there a possibility that another mutation locating on the adjacent region is involved in the observed phenotypes? In this context, if the progeny is generated from* Rasgrp1^Anaef^ *mice tha are ANA negative (*[*Figure 1D*](#fig1){ref-type="fig"}*), are they ANA positive*?

The fact that RasGRP1-deficient Jurkat T cells reconstituted with a Rasgrp1^Anaef^ allele and *Rasgrp1*^*Anaef*^ thymocytes demonstrated very similar Ras-ERK responses upon in vitro stimulation ([Figsures 4 and 5](#fig4 fig5){ref-type="fig"}) already argued against another mutation causing the phenotype in *Rasgrp1*^*Anaef*^ mice. However, to be certain there was no other mutation closely linked to the *Rasgrp1*^*Anaef*^ mutation, whole-exome capture, sequencing and computational analysis were performed on DNA from an affected mouse. This identified the *Rasgrp1*^*Anaef*^ mutation as the only novel homozygous single-nucleotide variant on chromosome 2 between 104.9 Mb and 145.7 Mb, a wide interval in which each boundary was marked by two affected F2 mice that inherited recombined chromosomes ([Figure 1--figure supplement 1](#fig1s1){ref-type="fig"}). We added the following text:

"Whole-exome capture, sequencing and computational analysis of DNA from an affected mouse ([@bib4]) identified this mutation as the only novel single-nucleotide variant within the interval of interest on chromosome 2 (data not shown)."

*7) It might be interesting if the authors quickly review papers that have genetically deleted mTOR signaling in T cells to see if there might be differences in CD44 expression in those mice that might not have been emphasized in the original papers*.

We thank the reviewers for this suggestion and have added further details of the connection between CD44 levels and mTOR.

"This conclusion is reinforced by supplementary data from two studies: mice with a *neo*-insertion in an *Mtor* intron that decreases *Mtor* mRNA approximately 70% show a similar selective lowering of CD44 on CD4^+^ T cells ([@bib74]) and CD44 levels are also reduced on naïve, CD62L-positive T cells that are deficient for the mTOR activator Rheb or deficient for the mTOR-interacting protein Rictor ([@bib16])..."

[^1]: These authors contributed equally to this work.

[^2]: These authors also contributed equally to this work.
